Eric L. Sievers

Jackson-Madison County General Hospital — United States

Medicine · Health Sciences

44h-index14.4kcitations155works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(43), Acute Myeloid Leukemia Research(32), HER2/EGFR in Cancer Research(24), Monoclonal and Polyclonal Antibodies Research(24), CAR-T cell therapy research(21)

Publications154 total

Concomitant Surgical Ablation Using a Novel Bipolar Radiofrequency Clamp: Outcomes from the TRAC-AF Registry
Journal of Clinical Medicine·2025Open Access
It's time to change how we vaccinate for measles
Vaccine·2025
Principles of Antibody Drug Development
2024Open Access
Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Postapproval Study by Society of Cardiovascular Angiography and Interventions Shock Stage
Journal of the American Heart Association·2024· 7 citedOpen Access
Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Post-Approval Study by SCAI Shock Stage
2023Open Access
Inundative, Dry-Powder, Inhaled Measles Vaccination to Prevent Deaths of Young Children in War-torn Regions
Open Forum Infectious Diseases·2023· 2 citedOpen Access
C-8 | Analysis of Impella for Treatment of Acute Myocardial Infarction and Cardiogenic Shock: Outcomes of the RECOVER III Post-Approval Study by SCAI Shock Stage
Journal of the Society for Cardiovascular Angiography & Interventions·2023Open Access
Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023Open Access
Data from Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
2023Open Access
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Data from Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
2023Open Access
Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
2023Open Access
Data from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure 2: Representative Hematology Data from Non-Human Primates Dosed with TTI-621. from TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
2023Open Access
Data from TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
2023Open Access
Supplementary Figure Legend from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure Legend from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure 2 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
Supplementary Figure 1: Gating strategy and representative dot plots for flow cytometry-based phagocytosis assay. from TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
2023Open Access
Supplementary Figure 1 from A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Dana A. Kennedy(12), Joseph D. Rosenblatt(9), Nancy L. Bartlett(9), Anas Younes(7), Irwin D. Bernstein(7), Andres Forero‐Torres(6), Joseph M. Connors(6), Frederick R. Appelbaum(6), Stephen M. Ansell(5), Emily K. Larsen(5), Ajay K. Gopal(4), Scott E. Smith(4), Kerry J. Savage(4), Robert Chen(4), John P. Leonard(4), Michelle A. Fanale(4), Michael R. Loken(4), Lisa D. Johnson(4), Robert A. Uger(4), Radhakrishnan Ramchandren(3)